Building on the theories of knowledge recombination, we argue that the external acquisition of technologies acts as a boundary spanning mechanism that impacts on the recipient firm’ subsequent technology development. The effect is moderated by two additional mechanisms, namely the retention of star scientists and the experience in upstream strategic alliances. We tested our hypotheses on a sample of 6208 USPTO patented technologies acquired by 350 biotechnology firms over the period 1980–2012. Findings reveal an inverted U-shaped effect of the pioneering nature of the acquired technology on firm's subsequent developments, in terms of (self) citations of firm's subsequent patents to the acquired one. Moreover, the main relationship is negati...
We analyze the diffusion and integration of external knowledge by distinguishing between the depth a...
Drawing on organizational learning theory, we investigate the technological performance implications...
In the context of increased pharmaceutical innovation deficits and Big Pharma blockbusters' patent e...
Building on the theories of knowledge recombination, we argue that the external acquisition of techn...
Building on the theories of knowledge recombination, we argue that the external acquisition of techn...
Building on the theories of knowledge recombination, we argue that the external acquisition of techn...
Building on the theories of knowledge recombination, we argue that the external acquisition of techn...
Patent strategy has become an essential part of technology development in R&D intensive industries. ...
We examine the effects of university-based star scientists on three measures of performance for Cali...
Recent years have seen a growth in strategic alliances, mergers and acquisitions and collaborative n...
<div><p>In the context of increased pharmaceutical innovation deficits and Big Pharma blockbusters’ ...
textabstractIn the context of increased pharmaceutical innovation deficits and Big Pharma blockbuste...
Recent years have seen a growth in strategic alliances, mergers and acquisitions and collaborative n...
We analyze the diffusion and integration of external knowledge by distinguishing between the depth a...
Drawing on organizational learning theory, we investigate the technological performance implications...
We analyze the diffusion and integration of external knowledge by distinguishing between the depth a...
Drawing on organizational learning theory, we investigate the technological performance implications...
In the context of increased pharmaceutical innovation deficits and Big Pharma blockbusters' patent e...
Building on the theories of knowledge recombination, we argue that the external acquisition of techn...
Building on the theories of knowledge recombination, we argue that the external acquisition of techn...
Building on the theories of knowledge recombination, we argue that the external acquisition of techn...
Building on the theories of knowledge recombination, we argue that the external acquisition of techn...
Patent strategy has become an essential part of technology development in R&D intensive industries. ...
We examine the effects of university-based star scientists on three measures of performance for Cali...
Recent years have seen a growth in strategic alliances, mergers and acquisitions and collaborative n...
<div><p>In the context of increased pharmaceutical innovation deficits and Big Pharma blockbusters’ ...
textabstractIn the context of increased pharmaceutical innovation deficits and Big Pharma blockbuste...
Recent years have seen a growth in strategic alliances, mergers and acquisitions and collaborative n...
We analyze the diffusion and integration of external knowledge by distinguishing between the depth a...
Drawing on organizational learning theory, we investigate the technological performance implications...
We analyze the diffusion and integration of external knowledge by distinguishing between the depth a...
Drawing on organizational learning theory, we investigate the technological performance implications...
In the context of increased pharmaceutical innovation deficits and Big Pharma blockbusters' patent e...